| Title: |
New Application of an Old Drug: Anti-Diabetic Properties of Phloroglucinol |
| Authors: |
Drygalski, Krzysztof; Maciejczyk, Mateusz; Miksza, Urszula; Ustymowicz, Andrzej; Godzień, Joanna; Buczyńska, Angelika; Chomentowski, Andrzej; Walczak, Iga; Pietrowska, Karolina; Siemińska, Julia; Pawlukianiec, Cezary; Czajkowski, Przemysław; Fiedorczuk, Joanna; Moroz, Monika; Modzelewska, Beata; Zalewska, Anna; Kutryb-Zając, Barbara; Kleszczewski, Tomasz; Ciborowski, Michał; Hady, Hady Razak; Foretz, Marc; Adamska-Patruno, Edyta |
| Contributors: |
Nutrition et obésités: approches systémiques (UMR-S 1269) (Nutriomics); Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU); Medical University of Gdańsk; Medical University of Białystok (MUB); Institut Cochin (IC UM3 (UMR 8104 / U1016)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité) |
| Source: |
ISSN: 1661-6596. |
| Publisher Information: |
CCSD; MDPI |
| Publication Year: |
2024 |
| Subject Terms: |
NAFLD; anti-spasmodic; diabetes; insulin resistance; lipid metabolism; liver steatosis; oxidative stress; phloroglucinol; MESH: Animals; MESH: Phloroglucinol; MESH: Rats; Wistar; MESH: Non-alcoholic Fatty Liver Disease; MESH: Hypoglycemic Agents; MESH: Oxidative Stress; MESH: Male; MESH: Diet; High-Fat; MESH: Mitochondria; MESH: Antioxidants; MESH: Humans; MESH: Insulin Resistance; [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry; Molecular Biology/Biochemistry [q-bio.BM]; [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry; Molecular Biology/Molecular biology; [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism |
| Description: |
International audience ; Phloroglucinol (PHG), an analgesic and spasmolytic drug, shows promise in preventing high-fat-diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) and insulin resistance. In Wistar rats, 10 weeks of PHG treatment did not prevent HFD-induced weight gain but significantly mitigated fasting hyperglycemia, impaired insulin responses, and liver steatosis. This protective effect was not linked to hepatic lipogenesis or AMP-activated protein kinase (AMPK) activation. Instead, PHG improved mitochondrial function by reducing oxidative stress, enhancing ATP production, and increasing anti-oxidant enzyme activity. PHG also relaxed gastric smooth muscles via potassium channel activation and nitric oxide (NO) signaling, potentially delaying gastric emptying. A pilot intervention in pre-diabetic men confirmed PHG’s efficacy in improving postprandial glycemic control and altering lipid metabolism. These findings suggest PHG as a potential therapeutic for NAFLD and insulin resistance, acting through mechanisms involving mitochondrial protection, anti-oxidant activity, and gastric motility modulation. Further clinical evaluation is warranted to explore PHG’s full therapeutic potential. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/39408621; PUBMED: 39408621; PUBMEDCENTRAL: PMC11477119 |
| DOI: |
10.3390/ijms251910291 |
| Availability: |
https://hal.science/hal-04791783; https://hal.science/hal-04791783v1/document; https://hal.science/hal-04791783v1/file/ijms-25-10291.pdf; https://doi.org/10.3390/ijms251910291 |
| Rights: |
info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.80612056 |
| Database: |
BASE |